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Abstract There is no unique optimal peritoneal dialysis
prescription for all children, although the goals of ultrafiltra-
tion and blood purification are universal. In turn, a better
understanding of the physiology of the peritoneal membrane,
as a dynamic dialysis membrane with an exchange surface
area recruitment capacity and unique permeability character-
istics, results in the transition from an empirical prescription
process based on clinical experience alone to the potential for
a personalized prescription with individually adapted fill
volumesanddwelltimes.Inallcases,theprescribedexchange
fill volume should be scaled for body surface area (ml/m
2),
and volume enhancement should be conducted based on
clinical tolerance and intraperitoneal pressure measurements
(IPP; cmH2O). The exchange dwell times should be
determined individually and adapted to the needs of the
patient, with particular attention to phosphate clearance and
ultrafiltration capacity. The evolution of residual kidney
function and the availability of new, more physiologic,
peritoneal dialysis fluids (PDFs) also influence the prescrip-
tion process. An understanding of all of these principles is
integral to the provision of clinically optimal PD.
Keywords Peritonealdialysis.Children.Fillvolume.
Dwelltime.Peritonealmembrane.Icodextrin
The peritoneal membrane is a dialysis membrane for the
peritoneal dialysis (PD) patient. Ideally, the permeability of the
peritoneum and the surface area membrane recruitment
capacity [1] should be determined as part of the prescription
process. Knowledge about the contact surface area recruitment
capacity [2, 3], the so called “wetted” membrane, and vascular
surface area changes [4, 5], is important because of the desire
to prevent hyperperfusion of the peritoneal membrane, as it
may contribute to the development of membrane failure [6–8].
Nevertheless, in practice, greater significance is given to
the following clinical parameters [9]:
– Choice of peritoneal dialysis fluid (PDF) [10], with
particular reference to dextrose concentration (and the
associated ability to meet ultrafiltration needs) and its
biocompatibility for peritoneal membrane preservation
– Tolerance of the prescribed fill volume, determined by
patient report, at times with the assistance of intra-
peritoneal pressure (IPP) measurement [11]
– Dwell time of dialysis exchanges adapted to the
individual patient’s needs [12]
All these factors play key roles in achieving adequate PD.
Finally, it must be emphasized that the PD prescription
should be individualized and adapted to achieve at least two
main goals: (1) adequate ultrafiltration to avoid hyper-
volemia because of its contribution to cardiovascular
morbidity and mortality, and (2) blood purification of
solute, not limited solely to urea [9, 13].
Peritoneal dialysis principles: physiology
of the peritoneal membrane
The peritoneal membrane is a dynamic dialysis membrane
[1, 14, 15]. The actual surface area that is in contact with
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in humans as measured by computed tomography [2, 3].
The size of the contact area is dependent upon a variety of
factors—including posture, with positive recruitment occur-
ring in the supine position—and fill volume, with a
progressive increase in recruitment taking place until the
fill volume is close to 1,400 ml/m
2 body surface area (BSA)
in children 2 years of age and older [4]. Peritoneal vascular
mesenteric perfusion and density of the functional pores of
the perfused capillaries determine the peritoneal vascular
exchange surface area [1, 15, 16]. This area is dynamically
affected by different factors, such as PDF composition, fill
volume size, and possibly inflammatory agents [4–8].
Physiology of the dialysis process through the peritoneal
barrier is complex [14, 15]. One of the most influential
factors is capillary permeability, described by the three-pore
model that addresses both the diffusive process and
convective mass transport [16]. The ultrasmall pores,
aquaporins, are involved in sodium-free water exchange,
the small pores (the most numerous pores) allow diffusion
to take place, and the large pores facilitate convective mass
transport. The concentration gradient of a solute between
the plasma and the dialysate, which is in contact with the
peritoneal surface area, along with solute-specific peritoneal
membrane permeability coefficient, are the determinants of
the solute diffusion capacity. Low molecular weight
compounds such as urea are preferentially cleared by the
diffusive exchange purification process. In contrast, a
pressure gradient governs ultrafiltration and the convective
mass transport of high molecular weight compounds such
as the “middle molecular weight” uremic toxins [9, 13].
This pressure gradient is the arithmetic sum of hydrostatic
and osmotic pressures. The hydrostatic pressure gradient
results from intravascular pressure and IPP. Osmotic
pressure could be the result of either crystalloid (i.e.
generated by diffusible solutes such as glucose in the
dialysate) or colloid (i.e. generated by nondiffusible solutes
such as albumin in the plasma or icodextrin in the
dialysate). Currently, the osmotic agent used most frequent-
ly in PDFs is dextrose, and the associated osmotic
crystalloid generated gradient is only transient: it decreases
secondary to the time-dependent diffusion of glucose from
the dialysate to the plasma. Conversely, icodextrin is a
polymer of glucose that is secondarily hydrolyzed into
maltose and has colloid osmotic properties, which allows
for the icodextrin-generated osmotic gradient to be more
sustained [10, 17–20].
Choice of peritoneal dialysis fluid
The peritoneal membrane is in contact with the PDF;
therefore, biocompatibility is of great importance for
maintaining PD as a viable long-term dialysis modality [1,
19]. This is an especially pertinent issue for the pediatric
patient. In automated peritoneal dialysis (APD), the most
commonly prescribed dialysis modality in children, contact
between the PDF and the peritoneal membrane is repeated
frequently over the course of a daily dialysis session, a fact
that may increase the significance of the solution’s
biocompatibility. A variety of PDF-related factors has been
implicated in the bioincompatibility process and may result
in deleterious effects on the peritoneal structure (diabeti-
form vascular changes) and function (ultrafiltration failure,
purification loss). These factors include glucose degrada-
tion products (GDPs), dialysate pH, buffer type (lactate in a
supraphysiologic concentration), and osmolality (glucose
concentration). The glucose used as an osmotic agent is in a
nonphysiological concentration, and thereby results in
direct toxicity. However, it is the GDPs generated by the
heat sterilization process that are the primary determinants
of peritoneal toxicity. The GDPs result in an increased
membrane thickness and, as noted above, a “diabetiform”
vasculopathy, initially with neoangiogenesis (hyperperme-
ability), and thereafter with fibrosis (hypopermeability) and
ultrafiltration failure. GDPs can also cross-link with
proteins and produce advanced glycosylated end products
(AGEs), which have been implicated in the loss of residual
kidney function [19]. High osmolality, acidity, and/or a
high lactate content have been associated with deleterious
effects on leucocyte and mesothelial cell function.
New PDFs, the development of which has taken prior
concerns into consideration, are now available [10, 19–21]
(Tables 1 and 2). It should be emphasized, however, that no
single PDF can necessarily achieve all of the dialysis
prescription goals, with optimal ultrafiltration and optimal
blood purification being the desired clinical targets. These
new, more physiologic, solutions differ from the conven-
tional ones in their production process, as reflected by the
development of two-compartment dialysis bags, and in their
composition with respect to the buffer agent, pH, osmotic
agent, and their GDP concentration. All new PDFs offer
enhanced biocompatibility by reducing GDP concentration.
Despite the availability of these solutions in some countries,
there is no consensus regarding the best PDF to prescribe
and whether bicarbonate is in fact the optimal buffer for all
new PDFs [6]. In children, the application of pH-neutral
solutions with a low concentration of GDPs and bicarbon-
ate or a bicarbonate/lactate mixture as buffer, has been
associated with better membrane preservation and im-
proved mesothelial cell function, as reflected by an
increased dialysate concentration of CA125 (see below)
[7, 8, 22]. The pH-neutral bicarbonate-based solutions
appear to have superior buffering capacity compared with
a lactate-based dialysis fluid in children undergoing APD
[8]. The nearly neutral pH PDFs have been shown to induce
1634 Pediatr Nephrol (2009) 24:1633–1642less pain at peritoneal filling and are associated with a
smaller increase in IPP for the same amount of fill volume
[5, 8, 11]. The impact of the improved biocompatibility on
leukocyte function and peritoneal defense requires addi-
tional study [19].
Icodextrin-containing solutions, an alternative to PDFs
using glucose as the osmotic agent, are characterized by the
generation of slow but sustained ultrafiltration [17, 18]. The
ultrafiltration that takes place over a long dwell time is with
a no or limited sodium-free filtrate, characteristic of
“colloid” ultrafiltration. Conversely, when the dialysis
solution has a high glucose concentration, the ultrafiltrate
is generated by an osmotic crystalloid gradient that results
in a more “pure water” filtrate, without sodium removal.
Whereas the use of icodextrin-containing PDFs in older
children produces results similar to those that occur in
Table 2 Characteristics of currently available single-bag peritoneal dialysis (PD) solutions [19]
Manufacturer Potential drawbacks Potential benefits
Lactate-buffered glucose
containing Dianeal®
Baxter Low pH Ease of manufacture; low cost
High GDP content
Poor peritoneal membrane
biocompatibility
Infusion pain
Local and systemic
glucose exposure
Icodextrin-containing;
lactate buffered
Baxter Hypersensitivity Sustained ultrafiltration
Low pH Preservation of RRF
Licensed for single
daily use only
Hypertonic glucose replacement
Lactate containing Reduced hyperglycemia
Improved short-term systemic
hemodynamic profile
Desirable effects on metabolic
profile and body composition
Amino-acid containing;
Nutrineal®
Baxter Low pH No GDPs
Licensed for single daily use
only (avoid exacerbation of
uremic symptoms and acidosis)
Avoid systemic and peritoneal
glucose exposure
Peritoneal membrane protection
Enhance nutrition
GDP glucose degradation product, RRF residual renal function
Table 1 Characteristics of currently available multibag peritoneal dialysis (PD) solutions [19]
Manufacturer Potential drawbacks Potential benefits
Lactate-buffered: Balance®,
Gambrosol Tri®
Fresenius Gambro More physiological pH, but not
neutral. Local and systemic
glucose exposure
Lower GDP levels
More physiological pH
Improved peritoneal membrane
biocompatibility
Preserved membrane defense
Lactate/bicarbonate-
buffered: Physioneal®
Baxter Local and systemic glucose
exposure. Does not eliminate
peritoneal lactate exposure
Lower GDP levels
More physiological pH
Improved peritoneal membrane
biocompatibility
Preserved membrane defense
Reduced infusion pain
Bicarbonate-buffered:
BicaVera®
Fresenius Local and systemic
glucose exposure
Lower GDP levels
More physiological pH
More peritoneal membrane
biocompatibility
Preserved membrane defense
Improved correction of acidosis
GDP glucose degradation product
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of decreasing ultrafiltration over a long dwell time (i.e. 10–
14 h) in infants and young children. It is therefore important
to determine on an individual basis the optimal dwell time
in infants/young children who are treated with icodextrin, in
each case adapting it to the rapidity of the osmotic gradient
loss over time [21, 23]. Whereas clinical experiences [17–
19] in both adults and children have been favorable for the
use of icodextrin during long dwell periods, giving rise to
both increased ultrafiltration and improved clearances, the
long-term experience in terms of peritoneal and systemic
biocompatibility has yet to be determined, particularly in
children [20, 21]. Indeed, icodextrin is associated with a risk
for sterile peritonitis and cutaneous intolerance [17, 19].
Amino-acid-containing solutions also avoid glucose
exposure and contain no GDPs [24]. Their application in
dialysis patients with hypoalbuminemia has resulted in an
improved nutritional state [19] in some studies. Little
information exists on the use of these solutions in children
[21]. Therefore, where available, their use remains restricted
to several clinical conditions, such as during a peritonitis
episode to counterbalance the enhanced protein loss, or
possibly in the case of severe malnutrition.
All in all, we believe in the concept that enhanced PDF
biocompatibility should improve patient outcome in terms
of peritoneal membrane integrity. Therefore, the new
biocompatible PDFs should be preferred over conventional
PDFs for children receiving chronic PD. In addition, and
despite their limited biocompatibility, the use of icodextrin-
containing dialysis solutions in children is a particularly
effective method to enhance ultrafiltration and even
maintain patients on PD despite the presence of a high
peritoneal membrane transport capacity.
Determination of exchange fill volume
In adults on continuous ambulatory peritoneal dialysis
(CAPD), the choice of an exchange fill volume is often
limited to the prescription of a full dialysis bag of 2 or 2.5 L,
without the capability of providing an individually adapted
prescription based on body weight or BSA. In pediatric care,
however, we must adapt the fill volume to the individual
child considering the wide morphologic differences between
infants and adolescents. A common question is: “What is the
optimal fill volume for children on PD”? Twenty years ago,
it was recommended that the fill volume be prescribed per
kilogram of body weight, 30–50 ml/kg, lower in infants than
in older children and lower at the initiation of dialysis so as
to increase the likelihood of patient tolerance. Unfortunately,
this approach led to prescriptions characterized by relatively
small fill volumes. This limited fill volume concept also
resulted in the false perception of the existence of differences
in peritoneal permeability between children and adults, with
a hyperpermeable peritoneal state presumably present in the
youngest patients, especially in infants [25–27]. All of this
could be explained by the “geometry of diffusion”, a concept
that addresses the rapid equilibration of solute that occurs
across the peritoneal membrane when using small fill
volumes. This rapid equilibration has been repeatedly
observed in infants prescribed a small fill volume over a
relatively large peritoneal membrane surface area. Subse-
quent scaling of the fill volume by BSA (ml/m
2), particularly
in infants and small children, avoids this issue and also
makes possible an accurate assessment of membrane
transport capacity through use of the peritoneal equilibration
test (PET) [9, 28–31]. Therefore, the fill volume prescribed
for children should be scaled to BSA to preclude the
provision of a fill volume that is too small and to prevent
the development of functional hyperpermeability and appar-
ent ultrafiltration failure due to a rapid loss of the glucose-
related osmotic crystalloid gradient [9, 19].
In children older than 2 years, the presumed optimal fill
volume should be increased stepwise close to the”upper
limit” of 1,200–1,400ml/m
2 for a nocturnal exchange in the
prone position [9]. A small fill volume has been associated
with an impaired statural growth rate [32] and with a
discrepancy between urea and creatinine transport (urea –
high; creatinine – low) [32–34]. Conversely, a fill volume
that is too large may contribute to patient morbidity by
causing complications such as pain, dyspnea, hydrothorax,
hernia formation, gastroesophageal reflux with anorexia,
and loss of ultrafiltration by enhanced lymphatic uptake [9,
29, 33]. Such morbidity, which is in part related to an
elevated IPP, could also result in patient nonadherence.
Therefore, increasing the fill volume above a peak volume
could result in reduced efficiency rather than improvement
[4, 35].
In infants younger than 2 years, the fill volume is based
more on tolerance than on an optimal dialytic exchange
volume; whereas an upper limit for fill volume of 800 ml/m
2
(or 30–50 ml/kg body weight) [9] is often suggested, an
individual clinical assessment of tolerance is of greatest
importance. The bedside measurement of IPP can potentially
be of assistance in this regard [11]( T a b l e3).
Table 3 Normal hydrostatic intraperitoneal pressure (IPP; cmH2O)
related to the intraperitoneal fill volume [IPV; ml/m
2 body surface area
(BSA)] [4]
IPP (cmH2O) IPV (ml/m
2 BSA)
In adults 13.4±3.1 1585±235
In children older than 2 years 5.2±2.6 600±50
8.2±3.8 990±160
14.1±3.6 1400±50
1636 Pediatr Nephrol (2009) 24:1633–1642Procedure for measuring intraperitoneal pressure (IPP)
[11]:
& The patient is invited to use the bathroom, if needed, to
empty his or her bladder
& The patient is then placed at rest, lying completely flat
& The connection is made to the peritoneal system
& Any fluid present in the abdominal cavity is drained. A
defined volume of PDF is then instilled
& The PD line is fixed vertically; there is no counterpres-
sure in the distal part of the measurement tubing
& The zero level of the column (on the graduated scale) is
set at the center of the abdominal cavity, on the medial
axillary line
& The connection of the line to the patient is opened
& The level of the column of dialysis fluid in the PD line
is read, with a scale graduated in centimeters after the
height of the column stabilizes, initially after inspiration
(IPPinsp) and then after expiration (IPPexp)
Mean IPP (cmH2O) is determined as follows:
Mean IPP ¼
IPPinspþIPPexp
2
In summary, the prescribed fill volume should be low
enough initially to be well tolerated by the patient but
thereafter should be modified, potentially with the use of
IPP [11] measurements, to achieve adequate ultrafiltration
and urea purification, both of which are directly related to
the size of the fill volume. The upper tolerated limit of IPP
is 18 cmH2O, with the normal pressure being 7–14 cmH2O
(Table 3).
Determination of exchange dwell time
In CAPD the dwell times are long, and therefore, the major
risk to dialysis efficiency is loss of the glucose-related
osmotic gradient, resulting in ineffective ultrafiltration and
dialysate reabsorption by the child. To limit this develop-
ment, hypertonic dialysate is often prescribed despite the
potential for enhanced peritoneal membrane toxicity related
to the quantity of glucose and GDPs [19]. Whereas the use
of dialysate with icodextrin as the osmotic agent is one
means by which the time-related dialysate reabsorption can
be limited in patients receiving CAPD, its application
should be limited to one exchange per day [19, 20].
Most children, however, are treated with APD, a choice
made to allow for better tolerance of a full peritoneal cavity,
as occurs in the supine position, and to meet the need for
short dwell times to limit dialysate reabsorption [9]. In most
cases, nocturnal APD is also more compatible with a
normal day life (i.e. uninterrupted schooling and parents’
work). It should be emphasized that short dwell-time
exchanges that occur with APD are more appropriate for
urea clearance than for phosphate clearance, important
clinically because of the association between hyperphos-
phatemia and both osteodystrophy and cardiovascular
disease [9, 12]. In fact, during a PET, the time needed to
achieve a dialysate over plasma concentration ratio of 50–
60% for phosphate is three to four times longer than it is for
urea [9, 12]. Short dwell-time exchanges are, in turn, most
likely to result in adequate ultrafiltration and urea purifica-
tion (Kt/Vurea)[ 36]. Long dwell-time exchanges, on the
other hand, favor higher creatinine and phosphate clearance
but with the risk of impaired ultrafiltration. Thus, whereas
an exchange dwell time of approximately 1 h appears to be
a typical choice for the initial APD prescription in children,
it should subsequently be reevaluated and possibly modi-
fied based upon the needs of the individual patient, taking
into consideration the patient’s growth, residual kidney
function, peritoneal membrane function, and the desired
clinical goals [5]: ultrafiltration (short dwell times) or
phosphate purification (longer dwell times). The peritoneal
membrane’s transport capacity can be determined clinically
with tests such as the PET.
Evaluation of peritoneal membrane function: solute
transfer and net ultrafiltration
The most widely used test of peritoneal membrane function
is the PET, developed and described by Twardowski in
1986 [37]. The test was designed to be performed during a
4-h dwell with a 2.27% glucose dialysis solution to evaluate
small solute transfer across the peritoneal membrane and
net ultrafiltration. In children, comparable studies have
been performed with 2.5% glucose dialysis solution (North
America, Japan) and 2.3% anhydrous glucose dialysis
solution (Europe) [30, 31]. With this test, a patient’s
membrane transport capacity is characterized as high,
high-average, low-average, or low [9, 26, 30, 31, 38]. A
test performed with a 3.86% glucose dialysis solution
provides more accurate information on ultrafiltration
capacity and facilitates assessment of sodium sieving, or
the maximum dip in dialysate over plasma sodium
concentration that typically occurs during the initial 30–90
min of dwell time [39]. This allows for evaluation of the
free water transport capacity through the aquaporins, or
water channels. In some children, the ultrafiltrate generated
using a 3.86% glucose solution for the PET may, however,
be a factor of discomfort or even intolerance. Although
there is not a significant impact of using a 2.27% vs. 3.86%
glucose dialysis solution on transport group characteriza-
tion, the preceding exchange composition (e.g. icodextrin
vs. glucose) and dwell time can influence results of the
evaluation for protein transport during the PET [39, 40].
Therefore, it seems prudent to use the same PDF that is to
be used for the PET the night before the PET is to be
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important to recognize that the size of the test exchange fill
volume has a significant impact on the rapidity of solute
equilibration and the PET results [9, 25, 26]. If the text
exchange fill volume is scaled according to BSA, usually
1,000–1,100 ml/m
2, the test results appear to be most valid
and support the belief that there are no inherent differences
in the peritoneal membrane transport capacity when
comparing children of different ages or children to adults
[26–28, 38]. Conversely, a fill volume that is too low can
result in exchange hyperpermeability and rapid equilibra-
tion of solute across the peritoneal membrane because of
the small fill volume that results in a high solute D/P
(dialysate over plasma creatinine concentration) value and a
high absorption rate of glucose, with a resultant decreased
osmotic gradient [25, 26, 29]. In infants, however, the fill
volume used for the PET is usually the clinically prescribed
fill volume due to their limited tolerance of a high fill
volume until approximately 2 years of age. When using a
test exchange volume of 1,100 ml/m
2 in children initiating
PD, preliminary data suggest that a short PET, using only a
2-h dwell, may perform as well as the 4-h evaluation [41].
The ability to evaluate for ultrafiltration failure is also of
major clinical importance [2, 39]. In the case of low drain
volumes, a distinction must be made between catheter
dysfunction, leakage of fluid either externally through the
catheter tunnel or internally from the peritoneal cavity to
the pleural space, and impairment of the peritoneal
membrane. In fact, multiple membrane-related causes
should be considered, which include the following:
1. Large peritoneal surface area in comparison with the size
ofthefillvolume,theresultof eithertoolow a prescribed
fill volume or too large a vascular surface area secondary
to hyperperfusion (e.g. GDP-induced neoangiogenesis)
2. Impaired free-water transport as a result of aquaporin
dysfunction
3. High lymphatic absorption associated with a marked
elevation of IPP
4. Limited peritoneal surface area available for exchange,
as might occur with postinfectious or postsurgical
adhesions, peritoneal fibrosis, or peritoneal sclerosis
As mentioned above,free-watertransport characteristically
occurs during the first hour of a PETconducted with a 3.86%
glucosedialysissolutionandcontributesabout40–50%ofthis
early ultrafiltration [39]. When impaired ultrafiltration capac-
ity exists, one would expect to see little or no dip of the D/P
sodium as a result of impaired free-water clearance.
The personal dialysis capacity (PDC) test [42], which is
based on the three-pore model [16] and which is validated
in adults and in children [43], describes the peritoneal
membrane transport characteristics by functional parame-
ters, derived from data obtained following several
exchanges of different duration and different glucose
concentrations performed over an entire day. These param-
eters are: (a) the surface area over the diffusion distance,
which represents the total vascular surface area available for
diffusion and is thought to be comparable to the D/P value
of the PET; (b) the reabsorption parameter, primarily
representing lymphatic flow; and (c) the large pore flow,
which is reflected by the loss of protein/albumin from the
blood to the peritoneal cavity. A large pore flow that is higher
than expected according to the total vascular surface area
assessment appears to be the most sensitive sign of an
inflamed peritoneal membrane [44] and is correlated with
an increased mortality risk. Use of the PDC or placement of
dextran in the dialysis solution and subsequent analysis is the
best means by which to evaluate for enhanced lymphatic
absorption. Despite all the information given by the PDC test,
its use appears to be limited to a few pediatric dialysis centers,
predominantly those involved in PD-related research.
Dialysate cancer antigen 125 (CA125) concentration
within the dialysis effluent can be used as a marker of
mesothelial cell mass and thereby as a membrane integrity
parameter, but no clear correlation between these results
and peritoneal transport parameters have been established
[8, 19].
Finally, the dialytic removal of solute can be quantitated
by clearance (K) or mass transfer area coefficient (MTAC)
calculations. For urea, the clearance is scaled to the urea
volume of distribution (V), which is equivalent to total
body water. At present, V may be estimated using gender-
and height-adapted formulas for children [45]. The weekly
Kt/Vurea is derived from the daily value and in practice is
the principal quantitative factor used to characterize PD
adequacy [46]. Creatinine clearance (Kcreat) is another
clearance measure and is calculated in milliliters per minute
and then converted to weekly Kcreat and expressed in liters
per 1.73 m
2 BSA. The residual kidney function is
calculated as the mean of creatinine and urea renal
clearances and should be integrated in urea and creatinine
dialytic adequacy parameters.
The MTAC characterizes the dialytic removal of solute
and is a measure that is essentially independent of dialysis
mechanics (e.g. exchange volume or dialysate glucose
concentration). Different formulas to calculate the MTAC
are available [30, 47–49].
Peritoneal dialysis efficiency: adequate prescription
before optimal adequacy
Ultrafiltration, water and sodium balance, and blood
purification for more than just urea are key treatment goals
of the PD prescription process. Overhydration is an
important problem in children receiving PD and is most
1638 Pediatr Nephrol (2009) 24:1633–1642notable when the residual kidney function-associated
diuresis is substantially decreased. A number of factors
may contribute to sodium and water retention. Dietary
compliance in terms of sodium and water consumption and
mechanical problems such as catheter dysfunction should
be excluded before implicating PD inadequacy as being the
result of either membrane failure or an inappropriate or
ineffective prescription. As mentioned previously, a PET
conducted with a 3.86% glucose dialysis solution can
determine the permeability of the peritoneal membrane to
solute, the amount of drained ultrafiltration (net ultrafiltra-
tion) over the 4-h dwell period, and the maximum dip in
D/P sodium, which reflects sodium-free water as a
reflection of aquaporin function. If the patient is found to
be a rapid transporter, the result of either a large peritoneal
surface area or a prescribed fill volume that is too low, he or
she may benefit from altering the dialysis prescription by
increasing the fill volume as tolerated and/or by shortening
of the dwell time during APD to improve ultrafiltration.
Children with a decreased sodium-free water transport and
no dip in D/P sodium after a 1- to 2-h dwell will not benefit
from the use of a higher dialysate glucose concentration. On
the other hand, they may enhance their ultrafiltration capacity
by using a long exchange with icodextrin, as might occur
during the day with APD or at night for those receiving CAPD.
If enhanced lymphatic reabsorption is a strong consideration,
anindirecttherapeuticadjustmentistodecreasethefillvolume,
with the hope that a decreased IPP may in fact reverse the
propensity for reabsorption.
Urea removal scaled for the urea volume of distribution,
Kt/Vurea, is the recommended parameter to use as a
surrogate for adequate dialysis, at least in the case of
CAPD [46]. Although little comparable information exists
for APD, Kt/Vurea, and sometimes Kcreat, is regularly
measured for patients on this modality as well [46, 50].
Historically, both Kt/Vurea and Kcreat were the recommen-
ded adequacy parameters for patients receiving CAPD, and
it was proposed that the ratio of the two parameters should
be 1 to 30 (e.g. Kt/Vurea 2.4 L/week and Kcreat 72 L/week)
[9]. Somewhat surprisingly, the same correction factor has
been used in general pediatric care when adjustments are
made in drug prescription from milligrams per kilogram
body weight to milligram per meter squared BSA. This is
in fact the bridge from a volume of distribution such as the
vascular blood compartment, to a whole cellular distribution,
such as the cell membrane area. Maintaining this ratio of
urea to creatinine purification also appears to be significant
from a physiologic perspective, as it pertains to both cellular
purification (e.g. uremic toxin compartment) and total body-
water purification (e.g. urea volume of distribution).
When a discrepancy in the clearance parameters exists
and the Kt/Vurea is deemed adequate and the Kcreat
inadequate [32, 51], this could be the result of a hyper-
permeable peritoneal membrane state or, as mentioned
previously, a fill volume that is too low, both of which
result in significantly greater removal of urea vs. creatinine
across the peritoneal membrane. As also noted above,
impaired growth has been reported to be [30] associated
with a clearance determination characterized by an ade-
quate Kt/Vurea and a low Kcreat. Thus, whereas it is often
difficult to reach both parameters of adequacy and the most
recent National Kidney Foundation Kidney Disease Out-
comes Quality Initiative (KDOQI) guidelines on PD
adequacy recommend the preferential use of Kt/Vurea as the
adequacy parameter, every effort should be made in the
prescription process to achieve the urea over creatinine
purification ratio [9, 34, 51]. This may be most pertinent in
the APD population, for whom Kcreat targets have recently
been published and in whom the relationship between Kcreat
and Kt/Vurea is much more variable than it is with CAPD [50].
Whereas the removal of urea by PD is proportional to
the daily amount of PDF prescribed, the efficiency of
creatinine and, possibly most importantly, phosphate
removal are related to contact time and clearance. In
practice, an enhanced fill volume will impact urea removal,
whereas an extended dwell time is necessary for optimal
phosphate removal [12, 36, 52]. Therefore, efficiency of the
long daytime exchange in patients receiving APD is
exceptionally important, and in some cases, the use of
icodextrin during the day, which characteristically counters
the absorption of dialysate over the extended hours, may be
most ideal and complements the short dwells that charac-
terize cycler dialysis overnight. A new generation of cyclers
that currently offers the possibility of changing fill volume,
dwell time, and dialysate composition for each cycle of the
overnight cycling procedure has great potential for further
contributing to improved dialysis efficiency.
Residual kidney function may have a significant impact
on patient outcome and can assume greatest significance in
situations in which target solute clearances fail to be
achieved solely by the dialysis process [53, 54]. Efforts to
preserve residual kidney function include the prevention of
nephrotoxic insults such as exposure to radiocontrast dye,
aminoglycoside antibiotics, and extracellular fluid (ECF)
volume depletion [46]. Preferential use of an angiotensin-
converting enzyme inhibitor/angiotensin receptor blocker
for blood pressure control has also been proposed [55].
Finally, it has been recommended that in children, the
prescription should be individualized and that the overall
clinical status of the patient is an outcome parameter that is
as important to monitor as Kt/Vurea and Kcreat when
determining the ideal patient prescription. True prescription
modification may be necessary to achieve target clearances
if there have been repeated bouts of peritonitis and a
resultant decreased dialysis clearance, or a loss of residual
kidney function. Likewise, growth and nutritional status
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dialysis purification process. The recent report by Fischbach
et al. on these clinical measures has, in turn, prompted
questions about whether the “best” dialysis modality is daily
PD or daily and intensified hemodiafiltration [56]. In most
instances, the lowest dialysis glucose concentration should be
used with PD, despite the fact that the absorption of glucose
maytheoreticallyprovidesomecaloricbenefittotheanorectic
patient; it should not replace adequate nutrition by being
included in the dietary prescription. It is also possible that the
use of PDFs with a high glucose concentration may result in
hyperglycemia and potentially limit the patient’sa p p e t i t e .
There is no uniformed optimal PD prescription for all
children, nor is there an optimal PDF. However, if the new,
more physiological, dialysis solutions are clearly shown to
improve peritoneal membrane function in humans [19, 21,
57], their preferential use in children should complement
improvements in technology. They will also enhance our
greater understanding of factors that alter the structure and
function of the peritoneal membrane to improve the
prescription process for the benefit of the pediatric patient
who has a lifetime of ESRD care before them.
Questions
(Answers appear following reference list)
1. Choice of PDF should take which of the following into
consideration:
A. Inflow pain is primarily related to PDF osmolality
B. GDPs induce peritoneal vascular neoangiogenesis
with diabetiform changes
C. Dialysate glucose concentration is associated with
little or no membrane toxicity
D. Short dwells, with reduced PDF to peritoneal
membrane time as prescribed in APD, limit PDF
related-membrane toxicity
2. Peritoneal fill volume is characterized by which of the
following:
A. Prescribed fill volume should be determined solely
by the child’s perceived clinical tolerance
B. Pain during peritoneal dialysis is only related to the
size of the fill volume
C. Measurement of IPP is an objective parameter of
the tolerance of a fill volume
D. Fill volume that is too small will induce
hypopermeability
3. Which of the following accurately describes the process
of peritoneal dialysis:
A. Dialysis solute removal is impacted by the size of
the fill volume
B. Dialysis solute removal is impacted by the pre-
scribed dwell time
C. Short dwell time improves ultrafiltration capacity
D. Long dwell time improves phosphate removal
E. Long dwell time is a risk factor for PDF reabsorption
F. All of the above
4. Reduced drained volume could be related to all but
which of the following:
A. Large peritoneal surface area
B. Small peritoneal surface area
C. Technical problems with the PD catheter
D. Low IPP
E. Hyperpermeable peritoneal membrane
5. Which of the following characterizes the peritoneal
equilibration test (PET):
A. A 1.36% glucose PDS should be used to assess
peritoneal membrane permeability and ultrafiltra-
tion capacities
B. PET fill volume should be 1,100 ml/m
2 BSA only
in infants
C. It helps characterize peritoneal membrane permeability
D. It should be performed successively with all
prescribed PDS, even with icodextrin
6. An important principle of dialysis efficiency is:
A. ThehighertheKt/Vurea, the better the child’so u t c o m e
B. There is no peak fill volume for dialytic removal of
urea
C. Dialytic removal of phosphate is fill-volume and
dwell-time dependent
D. Free-water ultrafiltration is unrelated to the func-
tion of the ultrasmall pores
References
1. Fischbach M, Dheu C, Seugé-Dargnies L, Delobbe JF (2007)
Adequacy of peritoneal dialysis: consider the membrane for
optimal prescription. Perit Dial Int 27(Suppl 2):S167–S170
2. Chagnac A, Herskovitz P, Weinstein T, Elyashiv S, Hirsh J,
Hammel I, Gafter U (1999) The peritoneal membrane in
peritoneal dialysis patients: estimation of its functional surface
area applying stereologic methods to computerized tomography
scans. J Am Soc Nephrol 10:342–346
3. Chagnac A, Herskovitz P, Ori Y, Weinstein T, Hirsh J, Katz M,
Gafter U (2002) Effect of increased dialysate volume on
peritoneal surface area among peritoneal dialysis patients. J Am
Soc Nephrol 13:2254–2259
4. Fischbach M, Haraldsson B (2001) Dynamic changes of the total
pore area available for peritoneal exchange in children. J Am Soc
Nephrol 12:1524–1529
5. Fischbach M, Terzic J, Chauvé S, Laugel V, Muller A, Haraldsson
B (2004) Effect of peritoneal dialysis fluid composition on
peritoneal area available for exchange in children. Nephrol Dial
Transplant 19:925–932
1640 Pediatr Nephrol (2009) 24:1633–16426. Mortier S, De Vriese AS, Van de Voorde I, Schaub TP, Passlick
Detjen J, Lameire NH (2002) Hemodynamic effects of peritoneal
dialysis solutions on the rat peritoneal membrane: role of acidity
buffer choice, glucose concentration, and glucose degradation
products. J Am Soc Nephrol 13:480–489
7. Schmitt CP, Haraldsson B, Doetschmann R, Zimmering M,
Greiner C, Böswald M, Klaus G, Passlick-Deetjen J, Schaefer F
(2002) Effects of pH neutral, bicarbonate-buffered dialysis fluid
on peritoneal transport kinetics in children. Kidney Int 61:
1527–1536
8. Haas S, Schmitt CP, Bonzel KE, Querfeld U, Fischbach M,
Jolm U, Arbeiter K, Schaub T, Schaefer F (2003) Improved
acidosis correction and recovery of mesothelial cell mass with
neutral-pH bicarbonate dialysis solution among children under-
going automated peritoneal dialysis. J Am Soc Nephrol
14:2632–2638
9. Fischbach M, Stefanidis CJ, Watson AR, European Paediatric
Peritoneal Dialysis Working Group (2002) Guidelines by an ad
hoc European committee on adequacy of the paediatric peritoneal
dialysis prescription. Nephrol Dial Transplant 17:380–385
10. Schröder CH (2004) Optimal peritoneal dialysis: choice of volume
and solution. Nephrol Dial Transplant 19:782–784
11. Fischbach M, Terzic J, Laugel V, Escande B, Dangelser C,
Helmstetter (2003) A. Measurement of hydrostatic intraperitoneal
pressure: a useful tool for the improvement of dialysis dose
prescription. Pediatr Nephrol 18:976–980
12. Fischbach M, Lahlou A, Eyer D, Desprez P, Geisert J (1996)
Determination of individual ultrafiltration time (APEX) and
purification phosphate time by peritoneal equilibration test.
Application to individual peritoneal dialysis modality prescription
in children. Perit Dial Int 16(Suppl 1):S557–S560
13. Goldstein SL (2004) Adequacy of dialysis in children: does small
solute clearance really matter? Pediatr Nephrol 19:1–5
14. Dedrick RL, Flessner MF, Collins JM, Schultz JS (1982) Is the
peritoneum a membrane? ASAIO J 5:1–8
15. Flessner MF (2005) The transport barrier in intraperitoneal
therapy. Am J Physiol Renal Physiol 288:433–442
16. Rippe B (1993) A three-pore model of peritoneal transport. Perit
Dial Int 13(Suppl 2):S35–S38
17. de Boer AW, Schröder CH, van Vliet R, Willems JL, Monnens
LA (2000) Clinical experience with icodextrin in children:
ultrafiltration profiles and metabolism. Pediatr Nephrol 15:
21–24
18. Michallat AC, Dheu C, Loichot C, Danner S, Fischbach M (2005)
Long daytime exchange in children on CCPD: preservation of the
drained volume due to icodextrin use. Adv Perit Dial 21:195–199
19. McIntyre CW (2007) Update on peritoneal dialysis solutions.
Kidney Int 71:486–490
20. Schröder CH (2003) New peritoneal dialysis fluids: practical use
for children. Pediatr Nephrol 18:1085–1088
21. Canepa A, Verrina E, Perfumo F (2008) Use of new peritoneal
dialysis solutions in children. Kidney Int 73(Suppl 108):
S137–S144
22. Nau B, Schmitt CP, Almeida M, Arbeiter K, Ardissino G, Bonzel
KE, Edefonti A, Fischbach M, Haluany K, Misselwitz J, Kemper
MJ, Rönnholm K, Schaefer F, European Pediatric Peritoneal
Dialysis Study Group (2004) BIOKID: randomized controlled
trial comparing bicarbonate and lactate buffer in biocompatible
peritoneal dialysis solutions in children. BMC Nephrol 5:14
23. Dart A, Feber J, Wong H, Filler G (2005) Icodextrin reabsorption
varies with age in children on automated peritoneal dialysis.
Pediatr Nephrol 20:683–685
24. Canepa A, Verrina E, Perfumo F, Carrea A, Menoni S, Delucchi P,
Gusmano R (1999) Value of intraperitoneal amino acids in
children treated with chronic peritoneal dialysis. Perit Dial Int
19(Suppl 2):S435–S440
25. Kohaut EC, Waldo FB, Benfield MR (1994) The effect of changes
in dialysate volume on glucose and urea equilibration. Perit Dial
Int 14:236–239
26. Warady BA, Alexander S, Hossli S, Vonesh E, Geary D,
Kohaut E, for the Pediatric Peritoneal Dialysis Study
Consortium (1995) The relationship between intraperitoneal
volume and solute transport in pediatric patients. J Am Soc
Nephrol 5:1935–1939
27. de Boer AW, Van Schaijk TCJG, Willems HL, Reddingius RE,
Monnens LAH, Schröder CH (1997) The necessity of adjusting
dialysate volume to body surface area in pediatric peritoneal
equilibration tests. Perit Dial Int 17:199–202
28. Bouts AH, Davin JC, Groothoff JW, Van Amstel SP, Zweers MM,
Krediet RT (2000) Standard peritoneal permeability analysis in
children. J Am Soc Nephrol 11:943–950
29. Fischbach M, Terzic J, Menouer S, Haraldsson B (2000) Optimal
volume prescription for children on peritoneal dialysis. Perit Dial
Int 20:603–606
30. Warady BA, Alexander SR, Hossli S, Vonesh E, Geary D,
Watkins S, Salusky IB, Kohaut EC (1996) Peritoneal membrane
transport function in children receiving long-term dialysis. J Am
Soc Nephrol 7:2385–2391
31. Schaefer F, Langenbeck D, Heckert KH, Scharer K, Mehls O
(1992) Evaluation of peritoneal solute transfer by the peritoneal
equilibration test in children. Adv Perit Dial 8:416–415
32. Schaefer F, Klaus G, Mehls O, Mid European Pediatric
Peritoneal Dialysis Study Group (1999) Peritoneal transport
properties and dialysis dose affect growth and nutritional status
in children on chronic peritoneal dialysis. J Am Soc Nephrol
10:1786–1792
33. Durand PY (2000) Optimization of fill volumes in automated
peritoneal dialysis. Perit Dial Int 20:601–602
34. Malhotra D, Murata GH, Tzamaloukas AH (1997) Creatinine
clearance and urea clearance in peritoneal dialysis. What to do in
case of discrepancy. Perit Dial Int 17:532–535
35. Keshaviah P, Emerson PF, Vonesh EF, Brandes JC (1994)
Relationship between body size, fill volume and mass transfer
area coefficient in peritoneal dialysis. J Am Soc Nephrol 4:
1820–1826
36. Fischbach M, Desprez P, Terzic J, Lahlou A, Mengus L, Geisert J
(1996) Use of intraperitoneal pressure, ultrafiltration and purifi-
cation dwell times for individual peritoneal dialysis prescription in
children. Clin Nephrol 46:14–16
37. Twardowski ZJ, Nolph KD, Khanna R, Prowant BF, Ryan LP,
More HL (1986) Peritoneal equilibration test. Perit Dial Bull
7:138–147
38. Schaefer F (1998) Adequacy of peritoneal dialysis in children. In:
Fine RN, Warady BA (eds) CAPD/CCPD in children. Boston,
Kluwer Academic, pp 99–118
39. Smit W (2006) Estimates of peritoneal membrane function-new
insights. Nephrol Dial Transplant 21(Suppl 2):ii16–ii19
40. Twardowski ZJ, Prowant BF, Moore HL, Lou LC, White E, Farris
K (2003) Short peritoneal equilibration test: impact of preceding
dwell time. Adv Perit Dial 19:53–58
41. Warady BA, Jennings J (2007) The short PET in pediatrics. Perit
Dial Int 27:441–445
42. Haraldsson B (1995) Assessing the peritoneal dialysis capacities
of individual patients. Kidney Int 47:1187–1198
43. Schaefer F, Haraldsson B, Haas S, Simkova E, Feber J, Mehls O
(1998) Estimation of peritoneal mass transport by three-pore
model in children. Kidney Int 54:1372–1379
44. Van Biesen W, Van der Tol A, Veys N, Dequidt C, Vijt D, Lameire
N, Vanholder R (2006) The personal dialysis capacity test is
superior to the peritoneal equilib r a t i o nt e s tt od i s c r i m i n a t e
inflammation as the cause of fast transport status in peritoneal
dialysis patients. Clin J Am Soc Nephrol 1:269–274
Pediatr Nephrol (2009) 24:1633–1642 164145. Morgenstern BI, Wühl E, Nair KS, Warady BA, Schaefer F (2006)
Anthropometric prediction of total body water in children who are
on pediatric peritoneal dialysis. J Am Soc Nephrol 17:285–293
46. National Kidney Foundation (2006) K/DOQI Clinical Practice
Guidelines and Clinical Practice Recommendations for 2006
Updates. Hemodialysis Adequacy, Peritoneal Dialysis Adequacy
and Vascular Access. Am J Kidney Dis 48(Suppl 1):S91–S97
47. Morgenstern B, Pyle W, Gurskin A, Baluarte JH, Penman S,
Polinsky M, Kaiser B (1984) Transport characteristics of the
pediatric peritoneal membrane. Kidney Int 25:259–264
48. Geary D, Harvey E, Balfe J (1994) Mass transfer area coefficients
in children. Perit Dial Int 14:30–33
49. Lysaght MJ, Farrell PC (1984) Membrane phenomena and mass
transfer kinetics in peritoneal dialysis. J Membr Sci 44:5–53
50. Lo W-K, Bargman JM, Burkart J, Krediet RT, Pollock C, Kawanishi
H, Blake PG, ISPD Adequacy of Peritoneal Dialysis Working Group
(2006) Guideline on targets for solute and fluid removal in adult
patients on chronic peritoneal dialysis. Perit Dial Int 26:520–522
51. Durand PY, Freida P, Issad B, Chanliau J (1996) How to reach
optimal creatinine clearances in automated peritoneal dialysis.
Perit Dial Int 16(Suppl 1):S167–S170
52. Dombros N, Dratwa M, Feriani M, Gokal R, Heimbürger O, Krediet
R,PlumJ,RodriguesA,SelgasR,StruijkD,Verger C;EBPGExpert
Group on Peritoneal Dialysis (2005) European best practice guide-
lines for peritoneal dialysis. 7 Adequacy of peritoneal dialysis.
Nephrol Dial Transplant 20 (Suppl 9):ix24–ix27
53. Bargman JM, Thorpe KE, Churchill DN, CANUSA Peritoneal
Dialysis Study Group (2001) Relative contribution of residual
renal function and peritoneal clearance to adequacy of dialysis: a
reanalysis of the CANUSA study. J Am Soc Nephrol 12:
2158–2162
54. Chadha V, Blowey DL, Warady BA (2001) Is growth a valid
outcome measure of dialysis clearance in children undergoing
peritoneal dialysis? Perit Dial Int 21(Suppl 3):S179–S184
55. Fang W, Oreopoulos DG, Bargman JM (2008) Use of ACE
inhibitors or angiotensin receptor blockers and survival in patients
on peritoneal dialysis. Nephrol Dial Transplant doi:10.1093/ndt/
gfn321
56. Fischbach M, Terzic J, Menouer S, Dheu C, Soskin S, Helmstetter
A, Burger MC (2006) Intensified and daily hemodialysis in
children might improve statural growth. Pediatr Nephrol 21:1746–
1752
57. ter Wee PM, van Ittersum FJ (2007) The new peritoneal dialysis
solutions: friends only, or foes in part? Nat Clin Pract Nephrol
3:604–612
Answers:
1. B
2. C
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4. D
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